What is it about?
The article focuses on the treatment of hepatitis delta virus (HDV) infection, particularly in individuals co-infected with HIV. HDV, which only infects individuals already carrying the hepatitis B virus (HBV), causes the most severe form of chronic viral hepatitis, often leading to cirrhosis, liver cancer, or the need for liver transplantation. Historically, treatment options for HDV were limited and largely ineffective, but recent advances in antiviral therapies, such as bulevirtide and lonafarnib, offer new hope.
Featured Image
Photo by Steven Cornfield on Unsplash
Why is it important?
Addressing HDV effectively could significantly reduce liver-related morbidity and mortality globally while advancing the World Health Organization’s goal of eliminating viral hepatitis as a public health threat by 2030
Perspectives
The paper advocates for prioritizing HDV treatment within the HIV population and leveraging recent therapeutic advances to move toward curative strategies for this challenging disease.
Octavio Corral Pazos de Provens
Universidad Internacional de La Rioja
Read the Original
This page is a summary of: Treatment of hepatitis delta and
HIV
infection, Liver International, June 2022, Wiley,
DOI: 10.1111/liv.15345.
You can read the full text:
Contributors
The following have contributed to this page
